NCT07420582Completed
Antegrade Autologous Blood Reinfusion After CPB
The Effect of Antegrade Pump Blood Reinfusion Via Crystalloid "Chase" Technique on Postoperative Transfusion Requirements in Adult Cardiac Surgery Patients: A Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
This prospective observational study aims to evaluate the effect of antegrade pump blood reinfusion using the crystalloid "chase" technique on postoperative transfusion requirements in adult patients undergoing cardiac surgery with cardiopulmonary bypass. At the end of cardiopulmonary bypass, blood remaining within the cardiopulmonary bypass circuit is reinfused antegradely through the arterial line using a crystalloid chase, without collection or storage. Blood remaining within the bypass circuit after surgery represents a valuable source of autologous blood, and its reinfusion may contribute to perioperative blood conservation strategies. Patients receiving antegrade pump blood reinfusion via the chase technique will be compared with those managed without reinfusion, without any intervention by the investigators. The primary outcome is postoperative blood transfusion requirement.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 130 (actual)
- First submitted
- 12 Feb 2026
- Start date
- 23 Feb 2026
- Primary completion date
- 11 Aug 2026
- Lead sponsor
- Kocaeli City Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07420582
What you commit to
- Study type: Observational
- Participants enrolled: 130
- From 23 Feb 2026 to the primary completion date, 11 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concomitant cardiac procedures (e.g., valve repair/replacement or aortic surgery).
- Use of anticoagulant therapy without appropriate preoperative discontinuation according to current guideline recommendations.
- Use of non-steroidal anti-inflammatory drugs (NSAIDs) without appropriate discontinuation prior to surgery.
Other illness
- Emergency or Redo cardiac surgery
- Preoperative hematocrit \<30% or known inherited/acquired bleeding disorders.
- Active infection or systemic inflammatory/autoimmune disease.
- Active malignancy requiring ongoing treatment
Lab values
- Preoperative left ventricular ejection fraction \<30%.
- Thrombocytopenia (e.g., platelet count \<100×10³/µL) or abnormal coagulation tests.
- Use of any intraoperative allogeneic blood product (red blood cells, fresh frozen plasma, or platelets)
- Severe renal dysfunction (eGFR \<30 mL/min/1.73 m² or dialysis) and/or severe hepatic dysfunction (Child-Pugh B-C or coagulopathy).
Other
- Planned or intraoperative conversion to off-pump coronary artery bypass grafting
- Use of antiplatelet agents other than aspirin without appropriate discontinuation according to current guideline-recommended preoperative intervals.
- Refusal or inability to provide written informed consent.
Who the study is looking for
- Age 18 to 80 years
- Patients undergoing elective, isolated coronary artery bypass grafting surgery using cardiopulmonary bypass (on-pump).
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kocaeli City Hospital Coordinator of this site? Confirm its status | Kocaeli | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.